Idiopathic Pulmonary Fibrosis: Development, Treatment and Outcomes
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pulmonology".
Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 303
Special Issue Editor
Special Issue Information
Dear Colleagues,
In this Special Issue of Medicina entitled “Idiopathic Pulmonary Fibrosis: Development, Treatment and Outcomes”, we want to collect several interesting manuscripts of research in this field. Idiopathic pulmonary fibrosis (IPF) is a usually progressive fibrotic lung disease.
High-resolution computed tomography (HRCT) of the chest plays a major role in IPF diagnosis, as described in international guidelines. From an imaging perspective, COVID-19 prevails all over the world this year, and the distinction of IPF from COVID-19 is an important issue in emergency departments.
There is no standard management for IPF. However, anti-fibrotic agents are available in clinical practice. In the era of anti-fibrotic agents, there are still unmet needs for the long-term stabilization of disease behavior, the prevention of acute exacerbation (AE) or lung cancer, and so on. For the development of therapeutic drugs for IPF, further investigation of the pathogenesis of stable IPF and AE is warranted. Therefore, I propose the following questions for this Special Issue:
・What is the core pathogenesis of stable IPF and AE?
・What is the most useful prevention strategy for AE of IPF?
・How should we use chest HRCT for the diagnosis of and treatment response for IPF in the era of COVID-19?
・What are the diagnostic clues for IPF/usual interstitial pneumonia (UIP) with pathological specimens?
・How do we commence and maintain anti-fibrotic agents differently for the management of IPF?
Guest Editor: Dr. Tomoo Kishaba
Dr. Tomoo Kishaba
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute exacerbation
- anti-fibrotic agents
- chest HRCT
- pathogenesis
- pathology
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
